Clinical Trials Logo

Malignant Solid Neoplasm clinical trials

View clinical trials related to Malignant Solid Neoplasm.

Filter by:

NCT ID: NCT05102656 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Patient Perceptions of the Relational Empathy of Healthcare Practitioners From the Department of Emergency Medicine During the COVID-19 Pandemic

Start date: June 2, 2021
Phase:
Study type: Observational

This study investigates patients' perceptions of their doctor's or nurse's empathy during an in-person interaction with the doctor or nurse wearing personal protective equipment (PPE) compared to during a video interaction with the doctor or nurse without PPE. The goal of this research study is to learn whether patients who visit the Acute Cancer Care Center at MD Anderson believe they get better (more empathetic) care from doctors who visit them in person wearing PPE or from doctors who visit them by video call and do not wear PPE.

NCT ID: NCT05055011 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Parental Attitudes and Beliefs Regarding Risks Associated With Opioid Use in Children With Cancer

Start date: December 3, 2020
Phase:
Study type: Observational

This study investigates parents' attitudes and beliefs on the risks of opioid use in children with cancer. Pain is the common symptom reported by pediatric cancer patients. Opioids are the mainstay in the treatment of cancer-related pain. Despite an almost universal desire to prevent or mitigate pain in their children, parents exhibit complex behaviors from withholding prescribed opioids entirely to giving less than the prescribed analgesic dose of opioid to discontinuing despite ongoing pain. Information gathered from this study may help address a crucial knowledge gap in researchers' understanding of parental attitudes and beliefs regarding the risks associated with opioid use in children and adolescents.

NCT ID: NCT05023993 Active, not recruiting - Prediabetes Clinical Trials

The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer

Start date: June 23, 2022
Phase: N/A
Study type: Interventional

This trial studies the effect of exercise and nicotinamide riboside on muscle health and insulin resistance in adult survivors of childhood cancer with prediabetes (elevated blood sugar level that is not high enough to be considered diabetes). Nicotinamide riboside is a dietary supplement which is similar to vitamin B3. Information collected in this study may help the future development of regimens to improve metabolic outcomes such as muscle health and insulin resistance (when the body is not normally responding to insulin) in childhood cancer survivors.

NCT ID: NCT04940299 Active, not recruiting - Metastatic Melanoma Clinical Trials

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Start date: September 23, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial investigates the side effects of tocilizumab, ipilimumab, and nivolumab in treating patients with melanoma, non-small cell lung cancer, or urothelial carcinoma that has spread to nearby tissue or lymph nodes (locally advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Tocilizumab is a monoclonal antibody that may interfere with the immune system to decrease immune-related toxicities. Giving tocilizumab, ipilimumab, and nivolumab may kill more tumor cells.

NCT ID: NCT04905082 Active, not recruiting - Breast Carcinoma Clinical Trials

HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics

Start date: December 30, 2021
Phase: N/A
Study type: Interventional

This clinical trial studies the effectiveness of a web-based cancer education tool called Helping Oncology Patients Explore Genomics (HOPE-Genomics) in improving patient knowledge of personal genomic testing results and cancer and genomics in general. HOPE-Genomics is a web-based education tool that teaches cancer/leukemia patients, and patients who may be at high-risk for developing cancer, about genomic testing and provide patients with information about their own genomic test results. The HOPE-Genomics tool may improve patient's genomic knowledge and quality of patient-centered care. In addition, it may also improve education and care quality for future patients.

NCT ID: NCT04865133 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Efficacy and Safety of COVID-19 Vaccine in Cancer Patients

Start date: March 31, 2021
Phase:
Study type: Observational

This study gathers information about how a cancer patient responds to COVID-19 vaccine during cancer treatment compared to healthy individuals. The information gained may help determine how effective currently available COVID-19 vaccines are in cancer patients receiving chemotherapy and learn more regarding how long an immune response will last compared to healthy individuals.

NCT ID: NCT04745910 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

Start date: April 5, 2022
Phase: Phase 4
Study type: Interventional

This trial studies the effect of pegloticase in reducing uric acid levels in patients with hyperuricemia (high blood levels of uric acid) caused by tumor lysis syndrome. Tumor lysis syndrome occurs when the breakdown products of cancer cells, such as uric acid, enter the blood stream. High levels of uric acid in blood may cause kidney damage and reduce kidney function. The goal of this trial is to learn if pegloticase may lower uric acid levels in blood when given to cancer patients with hyperuricemia caused by tumor lysis syndrome.

NCT ID: NCT04742595 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Viral Specific T Cell Therapy for COVID-19 Related Pneumonia

Start date: December 18, 2020
Phase: Early Phase 1
Study type: Interventional

This early phase I trial identifies the feasibility, possible benefits and/or side effects of administering SARS-CoV-2 specific cytotoxic T lymphocytes (CTLs) in treating cancer patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the virus responsible for coronavirus disease 2019 (COVID-19). SARS-CoV-2 Specific CTLs are a type of immune cells that are made from donated blood cells grown in the laboratory and are designed to kill cells infected with SARS-CoV-2 virus. Giving CTLs may help control the COVID-19 in cancer patients.

NCT ID: NCT04650178 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials

Start date: May 26, 2020
Phase:
Study type: Observational

This study investigates the experiences of cancer patients with neuropathy during the COVID-19 pandemic to learn how the COVID-19 pandemic affects their quality of life and clinical outcomes. This study will also explore whether there are differences between patients who received neurofeedback (NFB, a type of therapy that is thought to help normalize brain activity) and those who did not. Learning about quality of life in cancer patients with neuropathy during the COVID-19 pandemic may help guide development of programs and policies to improve chronic pain patient care and outcomes during a major global healthcare crisis.

NCT ID: NCT04607590 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Yoga Program for Improving the Quality of Life in Couples Coping With Cancer

Start date: May 31, 2019
Phase:
Study type: Observational

This clinical trial seeks to learn if a yoga program can improve physical performance, quality of life and symptom burden in cancer patients who are undergoing radiation therapy, and their partners. Taking part in yoga or stretching sessions may lower distress, improve quality of life, and/or may improve sleep and fatigue for cancer patients and their caregivers.